LGD-4033 and Modafinil Interaction

Avoid
Mechanism-based 64% confidence

LGD-4033 and Modafinil have a potentially harmful interaction with 64% confidence. Both LGD-4033 and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Modafinil

Eugeroic | Wakefulness & Cognitive Enhancement

The exact mechanism of action of modafinil is not fully understood, which distinguishes it from most prescription stimulants. The primary mechanism appears to involve inhibition of the dopamine transporter (DAT), leading to increased extracellular dopamine concentrations in the nucleus accumbens and cortical regions.

Half-life: ~12-15 hours Typical dose: 100-200 mg/day cognitive
dopamine receptorgabaserotonin receptor blood pressure raisingcardiotoxichepatotoxicteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Brain
low

Shared Safety Flags

2x 2 compounds raise blood pressure (LGD-4033, Modafinil). Monitor BP daily and consider cardiovascular support.
2x 2 hepatotoxic compounds (LGD-4033, Modafinil). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (LGD-4033, Modafinil). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with Modafinil?

Combining LGD-4033 with Modafinil is not recommended. Both LGD-4033 and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Modafinil safe together?

This combination carries significant risk. Both LGD-4033 and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Modafinil?

Both LGD-4033 and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Modafinil?

LGD-4033 has a half-life of ~24-36 hours and Modafinil has a half-life of ~12-15 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Modafinil

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.